Cipla Ltd, one of India’s leading pharmaceutical companies, reported a stronger-than-expected second-quarter performance on Thursday, driven by sustained demand for its respiratory drugs and expanding chronic portfolio.
Record Quarter for Cipla
The company announced its highest-ever quarterly revenue, crossing Rs 7,500 crore, supported by robust profitability.
Cipla also maintained its second position in India’s chronic market, with chronic therapies now contributing 61.8% to total revenue.
Key segments such as urology, antidiabetes, cardiac, anti-infectives, and dermatology outpaced overall market growth during the quarter.
Cipla's Respiratory Supremacy Continues
Reinforcing its dominance in the respiratory segment, Cipla’s brands occupy all top five positions in the Indian market.
The company remains the largest pharma player by volume and added four brands with annual revenue exceeding Rs 100 crore year-on-year.
In the U.S., Cipla’s Albuterol inhaler continues to lead the market with a 22% share, having supplied over 50 million units cumulatively.
The company also reported progress in its peptide and biosimilar portfolio, with Lanreotide’s market share rising to 22% and the launch of Filgrastim, Cipla’s first biosimilar in the U.S.
Cipla Eyes Four Major Respiratory Launches by 2026
Looking ahead, Cipla expects to launch four major respiratory assets by calendar year 2026, including the much-anticipated gAdvair in Q4 FY26. Additionally, three peptide assets, including Liraglutide, are in the pipeline. Notably, three out of the four respiratory assets are filed from U.S. facilities, helping derisk the launches and strengthen its global respiratory franchise.
Cipla's Expanding Portfolio and Manufacturing Milestones
The quarter also saw six new product launches, including Cipla’s entry into Orthocare, aimed at widening its therapy coverage. The company now has two brands with trailing twelve-month (TTM) revenue above Rs 100 crore and five brands in the Rs 50–100 crore range.
Further bolstering its compliance track record, Cipla’s Bommasandra manufacturing facility in Bengaluru was classified as VAI (Voluntary Action Indicated) by the USFDA during the quarter, a key regulatory milestone supporting future U.S. launches.
With a powerful respiratory pipeline, expanding chronic presence, and strengthening U.S. operations, Cipla appears well-positioned to sustain growth momentum through FY26.
Record Quarter for Cipla
The company announced its highest-ever quarterly revenue, crossing Rs 7,500 crore, supported by robust profitability.
Cipla also maintained its second position in India’s chronic market, with chronic therapies now contributing 61.8% to total revenue.
Key segments such as urology, antidiabetes, cardiac, anti-infectives, and dermatology outpaced overall market growth during the quarter.
Cipla's Respiratory Supremacy Continues
Reinforcing its dominance in the respiratory segment, Cipla’s brands occupy all top five positions in the Indian market.
The company remains the largest pharma player by volume and added four brands with annual revenue exceeding Rs 100 crore year-on-year.
In the U.S., Cipla’s Albuterol inhaler continues to lead the market with a 22% share, having supplied over 50 million units cumulatively.
The company also reported progress in its peptide and biosimilar portfolio, with Lanreotide’s market share rising to 22% and the launch of Filgrastim, Cipla’s first biosimilar in the U.S.
Cipla Eyes Four Major Respiratory Launches by 2026
Looking ahead, Cipla expects to launch four major respiratory assets by calendar year 2026, including the much-anticipated gAdvair in Q4 FY26. Additionally, three peptide assets, including Liraglutide, are in the pipeline. Notably, three out of the four respiratory assets are filed from U.S. facilities, helping derisk the launches and strengthen its global respiratory franchise.
Cipla's Expanding Portfolio and Manufacturing Milestones
The quarter also saw six new product launches, including Cipla’s entry into Orthocare, aimed at widening its therapy coverage. The company now has two brands with trailing twelve-month (TTM) revenue above Rs 100 crore and five brands in the Rs 50–100 crore range.
Further bolstering its compliance track record, Cipla’s Bommasandra manufacturing facility in Bengaluru was classified as VAI (Voluntary Action Indicated) by the USFDA during the quarter, a key regulatory milestone supporting future U.S. launches.
With a powerful respiratory pipeline, expanding chronic presence, and strengthening U.S. operations, Cipla appears well-positioned to sustain growth momentum through FY26.
You may also like
West Bengal: Another man allegedly ends life in fear over electoral roll revision
Bengal municipalities' job case: ED probes role of shell companies used to divert proceeds of crime
Abhishek Nayar appointed Kolkata Knight Riders head coach ahead of IPL 2026
Can a legal partition be accomplished through the court? What is the process?
FM Nirmala Sitharaman embarks on 4-day official visit to Bhutan
